Korean J Transplant.  2022 Nov;36(Supple 1):S364. 10.4285/ATW2022.F-5037.

Liver resection after sorafenib therapy in advanced hepatocellular carcinoma: a case report

• Bayartugs B
• Byambaragchaa M
• Amankyeldi Y

• KMID: 2535240
• DOI: http://doi.org/10.4285/ATW2022.F-5037

Abstract

Background
Mongolia is the highest incidence of hepatocellular carcinoma country in the world. There are 64 new cases per 100,000 population are diagnosed in Mongolia every year. It means it is eight times higher than worldwide. Almost 3/4 cases diagnosed in late stage. Sorafenib is a molecular targeted therapy used in palliative treatment of advanced hepatocellular car-cinoma.
Methods
We present in this case report who had surgery after sorafenib treatment in advanced hepatocellular carcinoma.
Results
The young 41-year-old patient had a large 9.0×8.5×9.5 sized hepatocellular carcinoma in the left liver with left portal vein and anterior portal vein tumor thrombosis. The volumetry of left liver 24.9% and anterior section 42.5%. We recommended to patient sorafenib to avoid from SPSS. After taking 6 months of sorafenib with dose 800 mg per day the tumor size had de-creased, and anterior portal vein tumor thrombus was disappeared. We performed left hepatectomy with thrombectomy. There is no recurrence after 2-year posthepatectomy.
Conclusions
Sorafenib can downstage hepatocellular carcinoma and could represent a bridge to surgery and liver transplan-tation patients in a low-income country.